@article{e37b488e03e744afbef0a04c93292591,
title = "Podoplanin: An emerging cancer biomarker and therapeutic target",
abstract = "Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.",
author = "Harini Krishnan and Julie Rayes and Tomoyuki Miyashita and Genichiro Ishii and Retzbach, {Edward P.} and Sheehan, {Stephanie A.} and Ai Takemoto and Chang, {Yao Wen} and Kazue Yoneda and Jun Asai and Lasse Jensen and Lushun Chalise and Atsushi Natsume and Goldberg, {Gary S.}",
note = "Funding Information: This work was presented at the first International Meeting on PDPN Research hosted at Nagoya University with support from Proteintech (Founding Sponsor), Fox Rothschild, VWR, Sentrimed, and Rowan University. This work was supported in part with funding from the Osteopathic Heritage Foundation and New Jersey Health Foundation to GSG, the JSPS KAKENHI (Grant Number 25461674) to JA, the National Cancer Center Research and Development Fund (23-A-12), the Foundation for the Promotion of Cancer Research, the 3rd Term Comprehensive 10- Funding Information: Year Strategy for Cancer Control, and the Advanced Research for Medical Products Mining Programme of the National Institute of Biomedical Innovation (NIBIO) and JSPS KAKENHI (24659185 and 16H05311) to TM and GI, the British Heart Foundation (RG/ 13/18/30563) to JR, the Project for Cancer Research and Therapeutic Evolution (P-CREATE, No. 17cm0106205 h0002) and Medical Research and Development Programs Focused on Technology Transfer, Acceleration Transformative Research for Medical Innovation (ACT-MS, No. 17im0210607 h0002) from the Japan Agency for Medical Research and Development (AMED) to AT, and a Grant-in-Aid for Scientific Research on Innovative Areas “Chemistry for Multimolecular Crowding Biosystems” (JSPS KAKENHI 2617H06356) to AN. Publisher Copyright: {\textcopyright} 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.",
year = "2018",
month = may,
doi = "10.1111/cas.13580",
language = "English (US)",
volume = "109",
pages = "1292--1299",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",
}